The FDA should approve UniQure's AMT-130 for Huntington's disease

From the articleUniQure plunges as Huntington's trial data disappoints investors | ReutersAlso in UniQure’s Huntington’s Drug Shows Weaker Benefit After Four Years in Trial, UniQure's gene therapy continues to slow Huntington's progression after four years